📊 VIVS Key Takeaways
Is VivoSim Labs, INC. (VIVS) a Good Investment?
VivoSim Labs exhibits critical financial distress with negative stockholders' equity (-$1.1M), indicating balance sheet insolvency. The company is burning $10.8M annually in operating cash against minimal and declining revenue ($131K, -9% YoY), leaving approximately 5-6 months of cash runway at current burn rates. Without immediate capital infusion, major revenue acceleration, or strategic partnership, the company faces acute bankruptcy risk.
VivoSim Labs has an extremely weak fundamental profile, with declining minimal revenue, an $11.49 million operating loss, and deeply negative operating cash flow. Although $5.02 million of cash and a 2.38x current ratio provide limited near-term liquidity, negative equity and a cash burn exceeding the asset base create severe financing, dilution, and going-concern risks.
VivoSim Labs, INC. Key Strengths (VIVS)
- Maintains $5.0M in cash providing near-term liquidity cushion
- No significant long-term debt obligations
- Operates in biological products sector with potential addressable market
- Current ratio of 2.38x indicates adequate coverage of near-term liabilities
- Cash and equivalents of $5.02 million represent a meaningful portion of total assets
- Zero reported capital expenditure limits additional investing cash demands
VIVS Stock Risks: VivoSim Labs, INC. Investment Risks
- Negative stockholders' equity of -$1.1M indicates balance sheet insolvency
- Operating cash burn of -$10.8M annually against only $5.0M cash reserves (~5-6 months runway)
- Revenue base of $131K is negligible, declining, and insufficient to support operations
- No capital expenditures suggest inability to fund product development or growth
- Zero insider Form 4 filings in 90 days indicates lack of management confidence
- Revenue declined 9.0% to only $131 thousand, indicating negligible and deteriorating commercial traction
- Negative $1.10 million stockholders' equity reflects balance-sheet insolvency
- Annual operating cash burn of $10.83 million substantially exceeds available cash and likely requires external financing
Key Metrics to Watch
- Cash balance depletion rate relative to monthly operating burn
- Revenue growth trajectory and path to profitability
- Announcement of financing, partnership, or strategic alternatives
- Quarterly operating cash burn and remaining cash runway
- Revenue growth and operating-loss reduction
VivoSim Labs, INC. (VIVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
VIVS Profit Margin, ROE & Profitability Analysis
VIVS vs Healthcare Sector: How VivoSim Labs, INC. Compares
How VivoSim Labs, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VivoSim Labs, INC. Stock Overvalued? VIVS Valuation Analysis 2026
Based on fundamental analysis, VivoSim Labs, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VivoSim Labs, INC. Balance Sheet: VIVS Debt, Cash & Liquidity
VIVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VivoSim Labs, INC.'s revenue has declined by 90% over the 5-year period, indicating business contraction. The most recent EPS of $-1.70 indicates the company is currently unprofitable.
VIVS Revenue Growth, EPS Growth & YoY Performance
VIVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2027 | $18.0K | -$1.3M | $-0.25 |
| Q3 2025 | $5.0K | -$2.7M | $-0.19 |
| Q2 2025 | N/A | -$2.5M | $-0.14 |
| Q1 2025 | $37.0K | -$2.8M | $-0.23 |
| Q3 2023 | N/A | -$3.3M | $-0.37 |
| Q2 2023 | N/A | -$3.3M | $-0.38 |
| Q1 2023 | N/A | -$2.5M | $-0.29 |
| Q3 2021 | N/A | -$2.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VivoSim Labs, INC. Dividends, Buybacks & Capital Allocation
VIVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VivoSim Labs, INC. (CIK: 0001497253)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VIVS
What is the AI rating for VIVS?
VivoSim Labs, INC. (VIVS) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are VIVS's key strengths?
Claude: Maintains $5.0M in cash providing near-term liquidity cushion. No significant long-term debt obligations. ChatGPT: Current ratio of 2.38x indicates adequate coverage of near-term liabilities. Cash and equivalents of $5.02 million represent a meaningful portion of total assets.
What are the risks of investing in VIVS?
Claude: Negative stockholders' equity of -$1.1M indicates balance sheet insolvency. Operating cash burn of -$10.8M annually against only $5.0M cash reserves (~5-6 months runway). ChatGPT: Revenue declined 9.0% to only $131 thousand, indicating negligible and deteriorating commercial traction. Negative $1.10 million stockholders' equity reflects balance-sheet insolvency.
What is VIVS's revenue and growth?
VivoSim Labs, INC. reported revenue of $131.0K.
Does VIVS pay dividends?
VivoSim Labs, INC. does not currently pay dividends.
Where can I find VIVS SEC filings?
Official SEC filings for VivoSim Labs, INC. (CIK: 0001497253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VIVS's EPS?
VivoSim Labs, INC. has a diluted EPS of $-5.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VIVS's fundamental grade?
Based on our AI fundamental analysis in August 2026, VivoSim Labs, INC. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VIVS stock overvalued or undervalued?
Valuation metrics for VIVS: ROE of N/A (sector avg: 15%), net margin of -10,567.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VIVS's AI grade for 2026?
Our dual AI analysis gives VivoSim Labs, INC. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VIVS's free cash flow?
VivoSim Labs, INC.'s operating cash flow is $-10.8M, with capital expenditures of $0.0. FCF margin is -8,264.9%.
How does VIVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,567.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.38 (avg: 2).